Weight-loss drug maker Novo Nordisk reported an earnings beat, but sales fell short of expectations. Management gave an encouraging outlook for the rest of 2025. Novo Nordisk trades for less than ...

Novo Nordisk CEO Lars Fruergaard Jørgensen to step down amid board and market pressure. Despite leadership changes, the company maintains its strategy. Unlock your all-in-one trading dashboard ...

Novo Nordisk has reduced its sales and profits forecasts for 2025 due to lower-than-expected demand in the US for blockbuster weight loss and diabetes drugs, though shares in the company were ...

May 16 - As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its ...

Novo Nordisk NOVO.B-2.41%decrease; red down pointing triangle shares rallied Wednesday as investors breathed a sigh of relief after first-quarter earnings beat expectations and the company’s ...

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug ...

Novo Nordisk announced Friday that Lars Fruergaard Jorgensen is stepping down by “mutual agreement” with the board—corporate speak for “things aren’t going well and someone has to take ...

Novo Nordisk NOVO.B-0.75%decrease; red down pointing triangle said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a ...

Novo Nordisk (NYSE: NVO) stock tumbled 3.9% through 10:45 a.m. ET this morning after the manufacturer of GLP-1 weight loss drugs announced its CEO, Lars Fruergaard Jørgensen, will step down from ...

COPENHAGEN (Reuters) - Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly ...

U.S.-listed shares of Novo Nordisk (NVO) are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered its full-year outlook. The maker of blockbuster weight-loss ...